0000000001012655

AUTHOR

Philip S. Wells

showing 3 related works from this author

Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboem…

2021

Background: The long-term risk for recurrent venous thromboembolism (VTE) during extended anticoagulation for a first unprovoked VTE is uncertain. Objectives: To determine the incidence of recurrent VTE during extended anticoagulation of up to 5 years in patients with a first unprovoked VTE. Methods: MEDLINE, EMBASE, and the Cochrane CENTRAL were searched to identify randomized trials and prospective cohort studies reporting recurrent VTE among patients with a first unprovoked VTE who were to receive anticoagulation for a minimum of six additional months after completing ≥3 months of initial treatment. Unpublished data on number of recurrent VTE and person-years, obtained from authors of in…

Pediatricsmedicine.medical_specialtypulmonary embolismanticoagulant therapy prognosis pulmonary embolism systematic review venous thromboembolism Anticoagulants Humans Prospective Studies Recurrence Risk Factors Pulmonary Embolism Venous Thromboembolismvenous thromboembolismMEDLINE030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineanticoagulant therapy; prognosis; pulmonary embolism; systematic review; venous thromboembolism; Anticoagulants; Humans; Prospective Studies; Recurrence; Risk Factors; Pulmonary Embolism; Venous ThromboembolismRandomized controlled trialsystematic reviewRecurrenceRisk FactorslawHumansMedicineProspective Studies030212 general & internal medicinecardiovascular diseasesProspective cohort studyanticoagulant therapybusiness.industryIncidence (epidemiology)AnticoagulantsHematologymedicine.diseaseequipment and supplies3. Good healthPulmonary embolismLong term riskMeta-analysisprognosisbusinessVenous thromboembolismprognosi
researchProduct

Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and met…

2021

BACKGROUND The long-term risk for major bleeding in patients receiving extended (beyond the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain. PURPOSE To determine the incidence of major bleeding during extended anticoagulation of up to 5 years among patients with a first unprovoked VTE, overall, and in clinically important subgroups. DATA SOURCES MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception to 23 July 2021. STUDY SELECTION Randomized controlled trials (RCTs) and prospective cohort studies reporting major bleeding among patients with a first unprovoked VTE who were to receive oral anticoagu…

Oralmedicine.medical_specialtymedicine.drug_classAdministration OralHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawRisk FactorsInternal medicineInternal MedicineMedicineHumansCumulative incidenceAge Factor030212 general & internal medicineProspective cohort study610 Medicine & healthAdministration Oral Age Factors Aged Anticoagulants Hemorrhage Humans Middle Aged Risk Factors Venous ThromboembolismAgedbusiness.industryIncidence (epidemiology)Risk FactorAnticoagulantAge FactorsAnticoagulantsGeneral MedicineVenous ThromboembolismVitamin K antagonistMiddle Aged3. Good healthConcomitantMeta-analysisAdministrationAdministration Oral; Age Factors; Aged; Anticoagulants; Hemorrhage; Humans; Middle Aged; Risk Factors; Venous ThromboembolismbusinessCohort studyHuman
researchProduct

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

2009

SummaryUnanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Malemedicine.medical_specialtyVitamin Kmedicine.drug_classAdministration OralHemorrhagePharmacotherapyInternal medicinemedicineCoagulopathyHumansInternational Normalized RatioProspective StudiesProspective cohort studyAgedAged 80 and overVenous ThrombosisVascular diseasebusiness.industryAnticoagulantWarfarinAnticoagulantsHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryFemaleINR oral anticoagulantsWarfarinbusinessFollow-Up Studiesmedicine.drugCohort studyThrombosis and Haemostasis
researchProduct